Print ISSN: 0027-1446

Online ISSN: 2309-6217

Keywords : Valsartan


The adjuvant effect of allopurinol with valsartan on the treatment of essential hypertension

Annals of the College of Medicine, Mosul, Volume 40, Issue 1, Pages 36-40
DOI: 10.33899/mmed.2018.159187

ABSTRACT
Background: Hyperuricemia is thought to contribute to development of hypertension, an elevation of uric acid in hypertension could be a consequence of reduced renal function, or elevated renal vascular resistance.
Objective: This paper aims to evaluate the adjuvant effect of allopurinol on blood pressure in newly diagnosed essential hypertensive patients with hyperuricemia.
Design: Double-blind randomized controlled clinical trial.
Patients and methods: Sixty newly diagnosed essential hypertensive patients with hyperuricemia in private clinic were enrolled in the study. They were randomly divided into two equal groups, group 1 was put on valsartan and allopurinol therapy, and group 2 was given valsartan and placebo therapy. Both groups were followed for four weeks duration. Blood pressure and serum uric acid levels were measured in both groups, before and after therapy.
Results: The systolic and diastolic blood pressures showed a significant reduction in group 1 with a mean difference of -24.20 ± 2.00 mmHg, for systolic blood pressure and -16.93 ± 4.73 mmHg for diastolic blood pressure. The reduction in serum uric acid was -3.25 ± 0.18, while the patients group that received valsartan and placebo did not show the same improvement.
Conclusion: The administration of allopurinol had beneficial effect on blood pressure, and can be used as adjunctive therapy for patients with hypertension, particularly if they have coexistent hyperuricemia..

Oxidant / antioxidant status and thyroid function tests in hypertensive patients treated by captopril or valsartan

Imad A. Thanoon; Shamil H. Othman

Annals of the College of Medicine, Mosul, Volume 38, Issue 2, Pages 62-67
DOI: 10.33899/mmed.2012.64599

ABSTRACT
Objectives: To assess, the oxidant / antioxidant status and thyroid function tests in newly diagnosed hypertensive patients and the effect of therapy with captopril or valsartan for 2 months on these parameters in comparison to healthy control subjects.
Methods: This study was conducted in Ibn-Sina Teaching Hospital, Consultative Clinic for Internal Medicine in Mosul city, from Jan. to Dec. 2008. Patients with certain criteria were included in this study. Blood samples were taken from the patients and assay of serum level of malondialdehyde (MDA), total antioxidant status (TAS) and thyroid hormones; [total triiodothyronine (T3), total thyroxine (T4) and thyroid stimulating hormone (TSH)] were done. They then started to receive either valsartan in the first group or captopril in the second group for 2 months after which another set of blood samples were taken and assayed for the same parameters mentioned above, were done. Forty apparently healthy subjects were also included in this study. They were recruited as a control group.
Results: Before starting therapy newly diagnosed hypertensive patients, had a significantly higher MDA serum levels and a significantly lower TAS, with non-significant differences in the levels of thyroid hormones (TT3, TT4 & TSH) in comparison to healthy controls. After 2 months of treatment with either captopril or valsartan, there was a significant decrease in MDA serum levels and a significant increase in TAS levels with non-significant effects on thyroid hormonal levels in comparison to pre-therapy stage.
Conclusion: Captopril and valsartan therapy improves oxidant / antioxidant status and carry no adverse effects on thyroid function in newly diagnosed patients with mild to moderate hypertension.

A comparison of the effects of valsartan and captopril monotherapy on hepatic enzymes activities

Ashraf H. Ahmed

Annals of the College of Medicine, Mosul, Volume 32, Issue 1, Pages 63-66
DOI: 10.33899/mmed.2006.8908

Objective: This study was conducted to assess the effect of valsartan and captopril, each as monotherapy in hypertensive patients, on hepatic enzymes activities including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP).Patients and methods: Thirty nine hypertensive patients were included in the study, 20 of them using captopril and 19 using valsartan. Serum ALT, AST, and ALP activities were measured before and after 2 months of starting treatment.Results: Patients on captopril showed significantly increased mean level of ALT and AST (P<0.001),( although still within normal limits) while mean ALP levels showed no significant difference. In the valsartan group, mean ALT, AST and ALP values showed insignificant differences.Conclusion: In hypertensive patients with liver disease, valsartan may be more suitable than captopril for the potential influence of the latter on serum transaminase levels.Keywords: captopril, valsartan, hepatic enzymes activities.